Order Article Reprints

Cucarull B, Tutusaus A, Subías M, Stefanovic M, Hernáez-Alsina T, Boix L, Reig M, García de Frutos P, Marí M, Colell A, et al. Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. Cancers. 2020; 12(2):332. https://doi.org/10.3390/cancers12020332

Cucarull, Blanca, Anna Tutusaus, Miguel Subías, Milica Stefanovic, Tania Hernáez-Alsina, Loreto Boix, María Reig, Pablo García de Frutos, Montserrat Marí, Anna Colell, and et al. 2020. "Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models" Cancers 12, no. 2: 332. https://doi.org/10.3390/cancers12020332

Cucarull, B., Tutusaus, A., Subías, M., Stefanovic, M., Hernáez-Alsina, T., Boix, L., Reig, M., García de Frutos, P., Marí, M., Colell, A., Bruix, J., & Morales, A. (2020). Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. Cancers, 12(2), 332. https://doi.org/10.3390/cancers12020332